Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02)

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GO-AHEAD
  • Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

  • 20 Apr 2021 Results (n=189) from open label extension of the GO-AHEAD study evaluating the long term efficacy and safety of golimumab in patients with axial spondyloarthritis, published in the Rheumatology
  • 26 Jun 2015 According to an MSD media release, the European Commission approved SIMPONI (golimumab) following the positive opinion of the CHMP for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) based on the findings from this GO-AHEAD study.
  • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top